MAPT and Alzheimer disease: Forty-eight participants, ≥60-years old, with amnestic MCI or early AD (CDR=0.5 or 1; NIA-Alzheimer’s Association criteria) and elevated tau protein, as determined by CSF Aβ:tau ratio, are eligible (Table 2).